SynoJoynt® 1% Sodium Hyaluronate
SynoJoynt® solution is a high molecular weight, non–cross-linked sodium hyaluronate derived from bacterial fermentation with excellent safety and tolerability.1 It is indicated for the treatment of pain from osteoarthritis of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics.
Reference 1. US Food and Drug Administration. Summary of safety and effectiveness (SSED) for SynoJoynt. Accessed January 5, 2022. https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170016B.pdf
INDICATIONS
SynoJoynt 1% sodium hyaluronate is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics (eg, acetaminophen).
CONTRAINDICATIONS
- Do not use SynoJoynt 1% sodium hyaluronate to treat patients who have a known hypersensitivity to hyaluronan preparations.
- Do not use to treat patients with knee joint infections or to treat patients with infections or skin disease in the area of the injection site.
WARNINGS
- Do not concomitantly use disinfectants containing quaternary ammonium salts or chlorhexidine for skin preparations because hyaluronan can precipitate in their presence.
- Do not inject intravascularly because intravascular injections of SynoJoynt 1% sodium hyaluronate may cause systemic adverse events.
SynoJoynt® solution is a high molecular weight, non–cross-linked sodium hyaluronate derived from bacterial fermentation with excellent safety and tolerability.1 It is indicated for the treatment of pain from osteoarthritis of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics.
Reference 1. US Food and Drug Administration. Summary of safety and effectiveness (SSED) for SynoJoynt. Accessed January 5, 2022. https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170016B.pdf
INDICATIONS
SynoJoynt 1% sodium hyaluronate is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics (eg, acetaminophen).
CONTRAINDICATIONS
- Do not use SynoJoynt 1% sodium hyaluronate to treat patients who have a known hypersensitivity to hyaluronan preparations.
- Do not use to treat patients with knee joint infections or to treat patients with infections or skin disease in the area of the injection site.
WARNINGS
- Do not concomitantly use disinfectants containing quaternary ammonium salts or chlorhexidine for skin preparations because hyaluronan can precipitate in their presence.
- Do not inject intravascularly because intravascular injections of SynoJoynt 1% sodium hyaluronate may cause systemic adverse events.